ADMA BIOLOGICS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
ADMA BIOLOGICS, INC. (ADMA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $616.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-25
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was $616.00K, a 28.54% decline from fiscal 2024.
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $862.00K, a 14.99% decline from fiscal 2023.
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $1.01M.
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was -$366.00K, a 258.44% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $616.00K 10-K · filed 2026-02-25 | |
| 2024-12-31 | $862.00K 10-K · filed 2026-02-25 | |
| 2023-12-31 | $1.01M 10-K · filed 2026-02-25 | $814.00K 10-K · filed 2024-02-28 |
| 2022-12-31 | -$366.00K 10-K · filed 2025-03-18 | -$154.60K 10-K · filed 2023-03-23 |
| 2021-12-31 | $231.00K 10-K · filed 2024-02-28 | $294.98K 10-K · filed 2022-03-24 |
| 2020-12-31 | $416.31K 10-K · filed 2022-03-24 | |
| 2019-12-31 | $474.23K 10-K · filed 2021-03-25 | |
| 2018-12-31 | $104.43K 10-K · filed 2020-03-13 | |
| 2017-12-31 | $100.81K 10-K · filed 2019-03-13 | |
| 2016-12-31 | $1.47M 10-K · filed 2018-03-29 | |
| 2015-12-31 | $602.39K 10-K · filed 2017-02-24 | |
| 2014-12-31 | $428.89K 10-K · filed 2016-03-23 | |
| 2013-12-31 | -$70.05K 10-K · filed 2015-03-09 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |